Open AccessExtensive intracranial arterial stenoses in conjunction with the use of tyrosine kinase inhibitor Nilotinib
Author(s) -
AlshiekhNasany Ruham,
Zidan Awss,
Martinez Carmen
Publication year - 2016
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.729
Subject(s) - nilotinib , medicine , tyrosine kinase inhibitor , myeloid leukemia , tyrosine kinase , acute coronary syndrome , cardiology , pharmacology , oncology , imatinib , myocardial infarction , cancer , receptor
Key Clinical Message New‐generation tyrosine kinase inhibitors ( TKI ) are promising agents for the treatment of chronic myeloid leukemia ( CML ), but the linkage to vascular diseases warrants a special attention from treating physicians, as it may carry major morbidity and mortality.